-
Mashup Score: 9
The latest FDA approval paves the way for expanded use of GLP-1 receptor agonists in patients without diabetes.
Source: www.pharmacytimes.comCategories: General Medicine News, PayerTweet
The latest FDA approval paves the way for expanded use of GLP-1 receptor agonists in patients without diabetes.
Semaglutide reduces cardiovascular risk in overweight patients, suggesting GLP-1 drugs may expand beyond diabetes treatment. #GLP1 #Semaglutide Read More: https://t.co/gP8vt7sT0S